These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 29616325)
1. Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E Lung; 2018 Jun; 196(3):313. PubMed ID: 29616325 [TBL] [Abstract][Full Text] [Related]
2. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642 [TBL] [Abstract][Full Text] [Related]
3. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032 [TBL] [Abstract][Full Text] [Related]
4. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Garnock-Jones KP Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393 [TBL] [Abstract][Full Text] [Related]
5. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Lian TY; Jiang X; Jing ZC Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514 [TBL] [Abstract][Full Text] [Related]
6. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Bishop BM Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133 [TBL] [Abstract][Full Text] [Related]
7. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517 [TBL] [Abstract][Full Text] [Related]
9. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669 [TBL] [Abstract][Full Text] [Related]
10. Riociguat for the treatment of pulmonary hypertension. Meis T; Behr J Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791 [TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. Frey R; Becker C; Saleh S; Unger S; van der Mey D; Mück W Clin Pharmacokinet; 2018 Jun; 57(6):647-661. PubMed ID: 29086344 [TBL] [Abstract][Full Text] [Related]
12. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Mielniczuk LM; Swiston JR; Mehta S Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043 [TBL] [Abstract][Full Text] [Related]
13. Modern view on the place of riociguat in the treatment of pulmonary hypertension. Valieva ZS; Taran IN; Martynyuk TV; Chazova IY Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875 [TBL] [Abstract][Full Text] [Related]